
Keywords: AE; adverse event; CFB; change from baseline; CNT; Coxib and tNSAID Trialists'; CrI; credible interval; CSR; clinical study reports; DIC; deviance information criterion; IGA; investigator global assessment; ITT; intention-to-treat; NMA; network meta-ana